Skip to main content
Clinical Trials/NL-OMON36731
NL-OMON36731Not yet recruitingNot Applicable

Pilot study to investigate whether oral phosphorus binders can reduce FGF23 levels and can influence vascular function as measured by pulse wave velocity in patiens with chronic kidney disease stage 3 (eGFR 30-60 ml/min/1,73 m2). - Effect van fosfaat verlaging op FGF23 en bloedvaten

Vrije Universiteit Medisch Centrum0 sites20 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
20

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • 1.patients with eGFR 30-60 ml/min/1,73 m2
  • 2.serum phosphorus level <1,49 mmol/L and >0,9 mmol/L
  • 3.age >18 year
  • 4.informed consent

Exclusion Criteria

  • 1. known allergy or intolerance for sevelamer-containing drugs
  • 2. patients with heart failure
  • 3. Use of phosphate binder therapy
  • 4. Patients dependent on tube-feeding or those with malabsorption syndrome
  • 5. rapidly deteriorating renal function
  • 6. pregnant woman
  • 7 patient with kidney transplantation

Investigators

Similar Trials